期刊文献+

Development of MEMS directed evolution strategy for multiplied throughput and convergent evolution of cytochrome P450 enzymes

原文传递
导出
摘要 Directed evolution(DE)inspired by natural evolution(NE)has been achieving tremendous successes in protein/enzyme engineering.However,the conventional"one-protein-for-one-task"DE cannot match the"multi-proteins-for-multi-tasks"NE in terms of screening throughput and efficiency,thus often failing to meet the fast-growing demands for biocatalysts with desired properties.In this study,we design a novel"multi-enzymes-for-multi-substrates"(MEMS)DE model and establish the proof-ofconcept by running a NE-mimicking and higher-throughput screening on the basis of"two-P450 s-against-seven-substrates"(2P×7S)in one pot.With the multiplied throughput and improved hit rate,we witness a series of convergent evolution events of the two archetypal cytochrome P450 enzymes(P450 BM3 and P450 cam)in laboratory.It is anticipated that the new strategy of MEMS DE will find broader application for a larger repertoire of enzymes in the future.Furthermore,structural and substrate docking analysis of the two functionally convergent P450 variants provide important insights into how distinct P450 active-sites can reach a common catalytic goal.
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2022年第3期550-560,共11页 中国科学(生命科学英文版)
基金 supported by the National Key Research and Development Program of China(2019YFA0706900) the National Natural Science Foundation of China(32025001,31872729,31600045,32071266,31800664,82022066,and 31800041) the Natural Science Foundation of Shandong Province,China(ZR2019ZD20,ZR2016CQ05,and ZR2019QC009) the Laboratory for Marine Drugs and Bioproducts of Pilot National Laboratory for Marine Science and Technology(Qingdao)(LMDBKF-2019-01) the Tianjin Synthetic Biotechnology Innovation Capability Improvement Project(TSBICIP-KJGG-001) the State Key Laboratory of Bio-organic and Natural Products Chemistry(SKLBNPC18242) the Fundamental Research Funds of Shandong University(2019GN030 and 2019GN033) the Foundation of Qilu University of Technology of Cultivating Subject for Biology and Biochemistry(No.202014)。
  • 相关文献

参考文献1

二级参考文献25

  • 1Ideura T, Muramatsu T, Higuchi M, Tachibana N, Hora K, Kiyosawa K. Tacrolimus/itraconazole interactions: a case report of ABO?incompatible living-related renal transplantation. Nephrol Dial Transplant 2000; 15: 1721-3.
  • 2Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006;26:868-71.
  • 3Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
  • 4Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, Dayer P. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin PharmacoI1999;55:559-65.
  • 5Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-1.
  • 6Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et at. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCijAUC) ratios. Drug Metab Dispos 2004; 32: 1201-8.
  • 7Food U, Administration D. Guidance for industry drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Food Drug Administration: Rockville, MD 2012.
  • 8Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789-94.
  • 9Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26: 395-403.
  • 10Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, et at. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol 2011; 163: 1250-62.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部